Adamis Pharmaceuticals(ADMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMP Adamis Pharmaceuticals

Pre-Market Trading 12-23 06:16:11 EST

0.7751

+0.0000

0.00%

High0.7751	Low0.7751	Vol0.00
Open0.7751	D1 Closing0.7751	Amplitude0.00%
Mkt Cap7.25M	Tradable Cap7.09M	Total Shares9.36M
T/O92.68K	T/O Rate0.00%	Tradable Shares9.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADMP","market":"US","secType":"STK","nameCN":"Adamis Pharmaceuticals","latestPrice":0.775063,"timestamp":1694116800000,"preClose":0.775063,"halted":8,"volume":0,"delay":0,"floatShares":9145028,"shares":9359133,"eps":-11.244462,"marketStatus":"Pre-Market Trading","change":0,"latestTime":"12-23 06:16:11 EST","open":0.775063,"high":0.775063,"low":0.775063,"amount":92678.1581832,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.244462,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734964200000},"marketStatusCode":1,"symbolChange":{"newSymbol":"DMK","executeDate":"2023-09-08"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.775063,"volumeRatio":0},"requestUrl":"/m/hq/s/ADMP/tweets","defaultTab":"tweets","newsList":[{"id":"2365935866","title":"Adamis changes name to DMK Pharmaceuticals, ticker to DMK","url":"https://stock-news.laohu8.com/highlight/detail?id=2365935866","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2365935866?lang=en_us&edition=fundamental","pubTime":"2023-09-08 02:41","pubTimestamp":1694112090,"startTime":"0","endTime":"0","summary":"Adamis Pharmaceuticals  is changing its name to DMK Pharmaceuticals  and its Nasdaq ticker symbol to DMK. Adamis said it was making the change to better reflect its new strategic focus on developing small molecule drugs to treat substance abuse disorders. Shares are expected to start trading under the new symbol on Friday.More on Adamis Pharmaceuticals  Financial information for Adamis Pharmaceuticals FVRR, CHRS and NBSE are among pre market gainers Adamis stock soars as high as 480% amid asset sale, drug study news","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323380788/image_1323380788.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323380788/image_1323380788.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4010036-adamis-changes-name-to-dmk-pharmaceuticals-ticker-to-dmk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":[".IXIC","BK4007","DMK","TQQQ","ADMP","BK4568","NQmain","QID","QQQ","MNQmain","PSQ","QLD","SQQQ"],"gpt_icon":0},{"id":"2365085021","title":"BRIEF-Adamis Pharmaceuticals Changes Name To DMK Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2365085021","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2365085021?lang=en_us&edition=fundamental","pubTime":"2023-09-08 00:18","pubTimestamp":1694103513,"startTime":"0","endTime":"0","summary":"Sept 7  - Adamis Pharmaceuticals Corp   :   * ADAMIS PHARMACEUTICALS CHANGES NAME TO DMK PHARMACEUTICALS TO REFLECT NEW STRATEGIC FOCUS   * ADAMIS PHARMACEUTICALS CORP - COMPANY'S COMMON STOCK IS EXPECTED TO TRADE UNDER NEW NASDAQ TICKER SYMBOL \"DMK\" ON OR ABOUT SEPTEMBER 8   * ADAMIS PHARMACEUTICALS CORP - DPI-125 WILL BE OUR CORE FOCUS   * ADAMIS PHARMACEUTICALS CORP - DMK EXPECTS SEVERAL POTENTIAL SIGNIFICANT MILESTONES FOR DPI-125 BY END OF 2024Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","DMK","ADMP","BK4007"],"gpt_icon":0},{"id":"2365850687","title":"Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2365850687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2365850687?lang=en_us&edition=fundamental","pubTime":"2023-09-07 16:00","pubTimestamp":1694073600,"startTime":"0","endTime":"0","summary":"Company to begin trading under new ticker symbol “DMK” on September 8, 2023SAN DIEGO, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biophar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2023/09/07/2739656/32832/en/Adamis-Pharmaceuticals-Changes-Name-to-DMK-Pharmaceuticals-to-Reflect-New-Strategic-Focus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DMK","BK4568","ADMP"],"gpt_icon":0},{"id":"2361063300","title":"Adamis Pharmaceuticals GAAP EPS of -$3.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2361063300","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2361063300?lang=en_us&edition=fundamental","pubTime":"2023-08-22 13:30","pubTimestamp":1692682258,"startTime":"0","endTime":"0","summary":"Adamis Pharmaceuticals press release  (NASDAQ:ADMP): Q2  GAAP EPS of -$3.40.\nRevenue of $6.95K\nCash and cash equivalents as of June 30, 2023, were approximately $0.6 million.\n\n\nMore on Adamis Pharmaceuticals  Adamis stock soars as high as 480% amid asset sale, drug study news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4004819-adamis-pharmaceuticals-gaap-eps-of-3_40","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ADMP"],"gpt_icon":0},{"id":"2361796215","title":"Adamis Pharmaceuticals Q2 EPS $(3.40) Up From $(4.20) YoY, Sales $6.95K Down From $39.85K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2361796215","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2361796215?lang=en_us&edition=fundamental","pubTime":"2023-08-21 21:19","pubTimestamp":1692623976,"startTime":"0","endTime":"0","summary":"Adamis Pharmaceuticals (NASDAQ:ADMP) reported quarterly losses of $(3.40) per share. This is a 19.05 percent increase over losses of $(4.20) per share from the same period last year.  The company reported $6.95 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/23/08/33962929/adamis-pharmaceuticals-q2-eps-3-40-up-from-4-20-yoy-sales-6-95k-down-from-39-85k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMP"],"gpt_icon":0},{"id":"2361579338","title":"Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2361579338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2361579338?lang=en_us&edition=fundamental","pubTime":"2023-08-21 13:15","pubTimestamp":1692594900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Aug.  21, 2023  (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2023/08/21/2728733/32832/en/Adamis-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMP","BK4007","BK4568"],"gpt_icon":0},{"id":"2360882165","title":"Aditxt, AlloVir top healthcare gainers; Evelo, Diffusion among losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2360882165","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2360882165?lang=en_us&edition=fundamental","pubTime":"2023-08-18 22:19","pubTimestamp":1692368367,"startTime":"0","endTime":"0","summary":"Losers:Evelo Biosciences  -37%.Diffusion Pharmaceuticals  -20%.TriSalus Life Sciences  -19%.Scilex Holding  -15%.Adamis Pharmaceuticals  -11%.S&P 500 Healthcare sector is currently down-0.32%to 1,551.53. Health Care Equipment & Services is down-0.02%.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487831223/image_487831223.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487831223/image_487831223.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4004365-aditxt-allovir-top-healthcare-gainers-evelo-diffusion-among-losers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SPY","BK4534","BK4588","AGEN","BK4504","ALVR","TLSI","OEX","BK4584","BK4183",".SPX","ADMP","EVLO","IVV","BK4559","BK4007","UPRO","BK4139","AKTX","SDS","BK4568","ADTX","BK4581","SSO","BK4557","OEF","VERU","CRVO","BK4550","SCLX","BK4585","SH","SPXU","ESmain"],"gpt_icon":0},{"id":"2360030259","title":"Li Auto, Keysight Technologies, XPeng among premarket losers' pack","url":"https://stock-news.laohu8.com/highlight/detail?id=2360030259","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2360030259?lang=en_us&edition=fundamental","pubTime":"2023-08-18 20:33","pubTimestamp":1692362023,"startTime":"0","endTime":"0","summary":"HIVE Digital Technologies  -7%on announcing amended at-the-market equity program.XPeng -8%after misses Q2 top and bottom line estimates; initiates Q3 outlook.See the stocks making thebiggest moves this morning.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4004307-li-auto-keysight-technologies-xpeng-among-premarket-losers-pack","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4024","FUBO","AHI","BK4524","HIVE","CRVO","BGLC","GGE","BK4134","LU1992135399.USD","FTCH","BK4563","CLSK","IREN","WRNT","IE00BD6J9T35.USD","BK4507","KEYS","EL","BK4505","LI","BK4170","XPEV","BITF","BK4183","BK4509","BK4526","MARA","IE00BMPRXR70.SGD","ADMP","IONQ","LU2552382058.USD","PRZO","SCLX","BK4023","EVS.SI","BK4077","HUT","BK4157","BK4503","BK4568","BK4588","VIPS","SDIG","LU2552382132.HKD","IE00BMPRXN33.USD","BK4504","HKIT","BK4585","BK4591"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adamispharmaceuticals.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.141707},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.016708},{"month":3,"riseRate":0.25,"avgChangeRate":-0.151319},{"month":4,"riseRate":0.416667,"avgChangeRate":0.005801},{"month":5,"riseRate":0.5,"avgChangeRate":-0.044858},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.014152},{"month":7,"riseRate":0.25,"avgChangeRate":0.000883},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.09042},{"month":9,"riseRate":0.583333,"avgChangeRate":-0.00078},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.052659},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.088803},{"month":12,"riseRate":0.5,"avgChangeRate":-0.069741}],"exchange":"NASDAQ","name":"Adamis Pharmaceuticals","nameEN":"Adamis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adamis Pharmaceuticals(ADMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adamis Pharmaceuticals(ADMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adamis Pharmaceuticals,ADMP,Adamis Pharmaceuticals股票,Adamis Pharmaceuticals股票老虎,Adamis Pharmaceuticals股票老虎国际,Adamis Pharmaceuticals行情,Adamis Pharmaceuticals股票行情,Adamis Pharmaceuticals股价,Adamis Pharmaceuticals股市,Adamis Pharmaceuticals股票价格,Adamis Pharmaceuticals股票交易,Adamis Pharmaceuticals股票购买,Adamis Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adamis Pharmaceuticals(ADMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adamis Pharmaceuticals(ADMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction